Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cerevel Therapeutics : Morgan Stanley Adjusts Cerevel Therapeutics Holdings PT to $39 From $27, Maintains Overweight Rating

09/07/2021 | 10:21am EST


ę MT Newswires 2021
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
01/10CEREVEL THERAPEUTICS TO PRESENT AT 4 : Additional Details of Phase 2 Program for Emraclidi..
AQ
01/05JPMorgan Starts Cerevel Therapeutics Holdings at Overweight With $50 Price Target
MT
01/03Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021Cerevel Agrees Multi-year Collaboration With Herophilus to Research, Develop Therapeuti..
MT
2021HC Wainwright Starts Cerevel Therapeutics Holdings at Buy With $50 Price Target
MT
2021CVL-231 : Results From an Early Proof-Of-Concept Study in Patients With Schizophrenia
PU
2021CEREVEL THERAPEUTICS : Evaluation of M4 Muscarinic Receptor Occupancy by CVL-231 in Nonhum..
PU
2021Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates ..
PU
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -221 M - -
Net cash 2021 609 M - -
P/E ratio 2021 -14,7x
Yield 2021 -
Capitalization 3 500 M 3 500 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 168
Free-Float -
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 23,77 $
Average target price 47,80 $
Spread / Average Target 101%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.-26.68%3 500
GILEAD SCIENCES, INC.-5.16%86 377
REGENERON PHARMACEUTICALS-1.05%65 339
VERTEX PHARMACEUTICALS10.66%61 849
WUXI APPTEC CO., LTD.-11.62%47 600
BIONTECH SE-37.08%39 180